Las Condes 26 03

115 / 164

375
[TRASPLANTE PULMONAR: ESTADO ACTUAL - Dra. María Teresa Parada C. y col.]
for long-term survival after lung transplantation and implications for
the lung allocation score. J Heart Lung Transplant 2010;29:731–738.
9. Woodrow JP, Shlobin OA, Barnett SD, et al. Comparison of bronchiolitis
obliterans syndrome to other forms of chronic lung allograft dysfunction
after lung transplantation. J Heart Lung Transplant 2010; 29: 1159–1164.
10. Sato M, Waddell TK, Wagnetz U, et al. Restrictive allograft syndrome
(RAS): a novel form of chronic lung allograft dysfunction. J Heart Lung
Transplant 2011; 30: 735–742.
11. Weill D et al . A consensus document for the selection of lung transplant
candidates:2014. J Heart Lung Transplant ;34 (1) Jan 2015.
12. Miñambres E, Pérez-Villares JM, et al. Lung donor treatment protocol in
brain dead-donors: A multicenter study. The Journal of Heart and Lung
Transplantation, Article in press
13. Munshi L, Keshavjee S, Cypel M. Donor management and lung
preservation for lung Transplantation.
Vol 1 June 2013
14. Ashley A. Vo., Marina Lukovsky,, Mieko Toyoda, Jennifer Wang, Nancy L.
Reinsmoen, Chih-Hung Lai et al. Rituximab and Intravenous Immune
Globulin for Desensitization during RenalTransplantation. N Engl J Med
2008;359: 242-51.
15. Parada MT, Alba A, Sepúlveda C, et al. Long-term use of everolimus in
lung transplant patients. Transplant Proc 2011; 43:2313–2315.
16. Christie JD, Carby M, Bag R, et al. Report of the ISHLT Working
Group on Primary Lung Graft Dysfunction part II: definition. A
consensus statement of the International Society for Heart and Lung
Transplantation. J Heart Lung Transplant 2005; 24: 1454–1459.
17. De Perrot M, Bonser RS, Dark J, et al. Report of the ISHLT Working Group
on Primary Lung Graft Dysfunction part III:donor-related risk factors
and markers. J Heart Lung Transplant 2005; 24: 1460–1467.
18. Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and
pneumonitis: impact after isolated lung transplantation. Am J Respir
Crit Care Med 1993; 147: 1017–1023.
19. Arthurs SK, Eid AJ, Deziel PJ, et al. The impact of invasive fungal diseases
on survival after lung transplantation. Clin Transplant2010; 24: 341–
348.
20. Parada MT, Alba A, Sepúlveda C. - Bronchiolitis obliterans syndrome
development in lung transplantation patients. Transplant Proc. 2010
Jan-Feb;42(1):331-2
21. Girnita AL, McCurry KR, Iacono AT, et al. HLA-specific antibodies are
associated with high-grade and persistent recurrent lung allograft
acute rejection. J Heart Lung Transplant 2004; 23: 1135–1141
22. Richard R Watkins,Tracy L Lemonovich . Immune response to CMV
insolid organ transplantrecipients: current conceptsand future
directions. Expert Rev. Clin. Immunol. 8(4), 383–393 (2012)
23. Hadjiliadis D, Duane Davis R, Steele MP, et al. Gastroesophageal reflux
disease in lungt ransplant recipients. ClinTransplant 2003;17: 363–3
68.
24. Parada MT, Sepúlveda C, Alba A, Salas A. .- Malignancy development
in lung transplant patients. Transplant Proc. 2011 Jul-Aug;
43(6):2316-7.
25. Kugler C, Fischer S, Gottlieb J, et al. Symptom experience after
lung transplantation: impact on quality of life and adherence. Clin
Transplant 2007; 21: 590–596.
26. Vermuelen KM, van der Bij W, Erasmus ME, et al. Long-term health-
related quality of life after lung transplantation: different predictors for
different dimensions. J Heart Lung Transplant 2007;26:188–193
27. Yamamoto S, Nava RG, Zhu J, et al. Cutting Edge: Pseudomonas
aeruginosa abolishes established lung transplant tolerance by
stimulating b7 expression on neutrophils. J Immunol 2012;
189:4221–4225.
28. Valapour M, Paulson K, Smith JM, Hertz MI, Skeans MA, Heubner
BM,Edwards LB, Snyder JJ, Israni AK, Kasiske BL. OPTN/SRTR 2011
annual data report: lung. Am J Transplant 2013; 13:149–177
29. Cypel, M, Yeung J, Liu M, et al. Normothermic Ex Vivo Lung Perfusion in
Clinical Lung Transplantation. N Engl J Med 2011;364:1431-40.
30. Machuca TN, Cypel M. Ex vivo lung perfusion. J Thorac Dis
2014;6(8):1054-1062